Nicotinamide Mononucleotide Ameliorates Myocardial Fibrosis in Diabetic Mice Possibly by Modulating SIRT3 to Deacetylate GSK3β and Thereby Reducing the Phosphorylation of Smad3.

Ma Z, Yao L, Zhang K, Yang Y

Journal of cardiovascular translational research10 Aug 2026

PMID42573891DOI10.1007/s12265-026-10827-yPepBankPUB-42573891

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, NMN ameliorated myocardial interstitial fibrosis versus the diabetic group.
In plain wordsIn mice with diabetes, NMN reduced heart fibrosis compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseMyocardial interstitial fibrosis
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Diabetic mice exhibited pronounced myocardial interstitial fibrosis alongside significant alterations in cardiac structure and function.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389101
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, NMN ameliorated cardiac structural alterations versus the diabetic group.
In plain wordsIn mice with diabetes, NMN improved heart structure compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
MixedCardiac structure
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Diabetic mice exhibited pronounced myocardial interstitial fibrosis alongside significant alterations in cardiac structure and function.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389102
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, NMN ameliorated cardiac functional alterations versus the diabetic group.
In plain wordsIn mice with diabetes, NMN improved heart function compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseCardiac function
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Diabetic mice exhibited pronounced myocardial interstitial fibrosis alongside significant alterations in cardiac structure and function.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389103
04AnimalAnimal study (in vivo)Mechanism
In diabetic mice, NMN ameliorated elevated ac-GSK3β/GSK3β expression versus the diabetic group.
In plain wordsIn mice with diabetes, NMN reduced the ac-GSK3β/GSK3β ratio compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Decreaseac-GSK3β/GSK3β expression
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Additionally, the protein expression levels of ac-GSK3β/GSK3β, p-Smad3/t-Smad3, α-SMA, and Collagen I were elevated, while SIRT3 expression was reduced.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389104
05AnimalAnimal study (in vivo)Mechanism
In diabetic mice, NMN ameliorated elevated p-Smad3/t-Smad3 expression versus the diabetic group.
In plain wordsIn mice with diabetes, NMN reduced the p-Smad3/t-Smad3 ratio compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Decreasep-Smad3/t-Smad3 expression
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Additionally, the protein expression levels of ac-GSK3β/GSK3β, p-Smad3/t-Smad3, α-SMA, and Collagen I were elevated, while SIRT3 expression was reduced.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389105
06AnimalAnimal study (in vivo)Mechanism
In diabetic mice, NMN ameliorated elevated α-SMA expression versus the diabetic group.
In plain wordsIn mice with diabetes, NMN reduced α-SMA expression compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Decreaseα-SMA expression
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Additionally, the protein expression levels of ac-GSK3β/GSK3β, p-Smad3/t-Smad3, α-SMA, and Collagen I were elevated, while SIRT3 expression was reduced.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389106
07AnimalAnimal study (in vivo)Mechanism
In diabetic mice, NMN ameliorated elevated Collagen I expression versus the diabetic group.
In plain wordsIn mice with diabetes, NMN reduced Collagen I expression compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseCollagen I expression
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Additionally, the protein expression levels of ac-GSK3β/GSK3β, p-Smad3/t-Smad3, α-SMA, and Collagen I were elevated, while SIRT3 expression was reduced.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389107
08AnimalAnimal study (in vivo)Mechanism
In diabetic mice, NMN ameliorated reduced SIRT3 expression versus the diabetic group.
In plain wordsIn mice with diabetes, NMN increased SIRT3 expression compared with the diabetic group.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseSIRT3 expression
Study
mousen: not reported in source
Diabetic mice
Comparator
Diabetic group
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
NMN effectively ameliorated these changes.
2 context sentences(design, population, supporting numbers)
Summary · context
Additionally, the protein expression levels of ac-GSK3β/GSK3β, p-Smad3/t-Smad3, α-SMA, and Collagen I were elevated, while SIRT3 expression was reduced.
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
Report a problemFND-4257389108

Studies that did not test the peptide alone1

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

09AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Mechanism
In diabetic mice, 3-TYP inhibited the therapeutic benefits of NMN.
In plain wordsIn mice with diabetes, adding 3-TYP inhibited the benefits seen with NMN.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseInhibition of NMN benefits by 3-TYP
Study
mousen: not reported in source
Diabetic mice
Comparator
NMN without 3-TYP
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
The therapeutic benefits of NMN were effectively inhibited by 3-TYP.
1 context sentence(design, population, supporting numbers)
Summary · context
This study aims to investigate the therapeutic potential of NMN in alleviating type 2 diabetes-induced myocardial fibrosis.The experiment was comprised of control group, diabetic group, DM + NMN intervention group, and DM + NMN+3-TYP group.
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Report a problemFND-4257389109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.